Fingerprint
Dive into the research topics of 'Late-stage cancer patients remain highly responsive to immune activation by the selective TLR8 agonist motolimod (VTX-2337)'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Late-stage cancer patients remain highly responsive to immune activation by the selective TLR8 agonist motolimod (VTX-2337)
Gregory N. Dietsch, Tressa D. Randall, Raphael Gottardo, Donald W. Northfelt, Ramesh K. Ramanathan, Peter A. Cohen, Kristi L. Manjarrez, Mona Newkirk, James Kyle Bryan, Robert M. Hershberg
Research output: Contribution to journal › Article › peer-review
20
Scopus
citations